| Document |
Document Title |
|
WO/2009/141110A1 |
The invention relates to a method for the synthesis of 3α-hydroxy-chlormadinone acetate.
|
|
WO/2009/136629A1 |
Disclosed is a method for the screening of a compound having an activity to selectively modulate an androgen receptor. The method comprises the steps of: contacting a substance to be tested with a prostate cancer cell and measuring the ...
|
|
WO/2009/069032A2 |
This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to th...
|
|
WO/2008/157652A1 |
The present application describes deuterium-enriched fluticasone propionate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
WO/2008/148473A2 |
The invention relates to a method for producing 17α-acetoxy-6-methylenepregn-4-ene-3,20-dione (4) as an intermediate preparation as well as methods for producing medroxyprogesterone acetate (1) (17α-acetoxy-6α-methylpregn-4-ene-3,20-d...
|
|
WO/2008/119918A1 |
Compounds of the formula (I) are provided having a steroid skeleton and substitution characteristics in the A and B rings of the steroid skeleton effective for mineralocorticoid receptor antagonism, and rings C and D of the steroid skele...
|
|
WO/2008/110941A2 |
The invention relates to a new process of synthesis of a squalamine and/or trodusquemine precursor like 24-substituted oxy-7-substitutedoxycholestan-3- one, preferably of 24β-benzoyloxy-7α-hydroxycholestan-3-one.
|
|
WO/2008/063128A1 |
Steroid compounds having increased resistance against metabolism and increased water solubilit y are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the trea...
|
|
WO/2007/089795A1 |
To provide an article support structure used when attaching an article to an adherend with a stretch- releas'able adhesive tape in which components and the like do not fly off when releasing the adhesive tape from the adherend, the doubl...
|
|
WO/2007/082891A1 |
The invention relates to the use of bacterial strains of the species Amycolatopsis mediterranei for the microbial transformation of 9β,10α-steroids of general Formula (I) to their corresponding 11β-hydroxyl analogues, as well as to sp...
|
|
WO/2007/082996A1 |
This invention concerns novel neutral labeling reactants. The novel reactants are deri- vatives of diethylenetriaminepentaacetic acid (DTPA) diamides, wherein a suitable group is linked to the molecule allowing introduction of the said n...
|
|
WO/2006/115304A1 |
It is intended to provide an agent for treating neuropathic pain which has an excellent therapeutic effect on neuropathic pain, which is an intractable disease. More particularly, it is intended to provide an agent for treating neuropath...
|
|
WO/2006/077209A1 |
A method for the preparation of medrogestone by heterogeneously palladium- catalysed isomerisation from 17-methyl-6-methylenepregn-4-ene-3,20-dione is described.
|
|
WO/2006/041121A1 |
It is intended to provide: a remedy and/or a preventive for a chronic skin disease which comprises, as the active ingredients, (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacologically acceptable salt thereof and (b) a steroid dr...
|
|
WO/2006/032885A2 |
The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of -OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide gr...
|
|
WO/2005/105822A2 |
The invention relates to a novel multi step process of making compounds of Formula (I), wherein R1 is an alkoxy group and R2 is an optionally substituted, N-attached heteroaryl. The hydrogen at the 5-position can be &agr or β isomer, pr...
|
|
WO/2005/082924A1 |
The invention provides new compounds of 23-Hetero-analogs of Ornithogalum caudatum saponin OSW-1, the preparation and use thereof. The present invention provides a practical process to synthesize the new 23-Hetero-OSW-1 saponin including...
|
|
WO/2005/058934A2 |
The present invention relates to novel glycosylated steroid compounds having anti-migratory activity. The present invention also relates to a method for the preparation of said glycosylated steroid compounds. The invention further relate...
|
|
WO/2005/044759A2 |
The present invention provides acetalization process for preparation of 16,17-acetals of pregnane derivatives from corresponding 16,17-dihydroxy compounds in phosphoric acid.
|
|
WO/2005/030221A1 |
A drug exhibiting an excellent therapeutic efficacy for ageing macular degeneration. In particular, a therapeutic agent for ageing macular degeneration characterized in that a progesterone derivative of the general formula: (1) (wherein ...
|
|
WO/2005/030120A2 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula (I) wherein the variables are defined in the specification.
|
|
WO2002042319A9 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula (I), wherein the variables are defined in the specification.
|
|
WO/2005/007668A1 |
A production process for 16-dehydropregnenoneol and its analogs is provided. In which, the psudosapogenin decomposed from steroid sapogenin, with or without purification, reacts with hydrogen peroxide in the organic solvent under the pre...
|
|
WO2003102012A9 |
The subject invention provides new progestogen esters and uses thereof.
|
|
WO/2004/101594A1 |
The invention relates to new mono- and bismethylene-steroid derivatives of general formula (I) - wherein Z represents two hydrogen atoms or an oxo group; X and Y independently of each other represent either two hydrogen atoms of a CH2= g...
|
|
WO/2004/094451A2 |
The invention relates to 8β-vinyl-11β-(&ohgr -substituted)alkyl-estra-1,3,5(10)-trienes of general formula (I), which have ERβ-antagonistic activity, methods for the production thereof, the intermediate products thereof, pharmaceutica...
|
|
WO/2004/078102A2 |
A process for the sterilization of water insoluble solid medicinal substances is described.The process provides the sterilization of beclomethasone, which is suitable for pulmonary administration. In particular, the process is used in in...
|
|
WO/2004/078709A2 |
Methods for the preparation of the 19-norprogesterone of formula I and its intermediates, in crystalline and amorphous forms.
|
|
WO/2004/060906A1 |
The present invention provides an improved process for the preparation of Guggulsterones which comprises epoxidising 16-dihydropegnenolone acetate (16 DPA) by reacting 16DPA with hydrogen peroxide reagent adduct in the presence of a co-b...
|
|
WO/2004/055039A1 |
The present invention relates to novel steroid compounds of Formula (IB) having anti-tumor activity. The present invention also relates to a method for the preparation of said steroid compounds. The invention further relates to a pharmac...
|
|
WO2004011663A9 |
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...
|
|
WO/2004/021975A2 |
The invention relates to an improved process for producing pharmacologically active synthetic stereoisomeric mixture of guggulsterones (4) in the three steps. The mixture of guggulsterones consists of Z-guggulsterone [4,17(20)-trans-preg...
|
|
WO/2003/092578A2 |
The present invention relates to improved methods for synthesising cyproterone acetate (17&agr -Acetoxy-6-chloro-1&agr , 2&agr -methylene-4,6-pregnadiene-3,20-dione) from solasodine. The methods of the invention are shorter as those of t...
|
|
WO/2003/078376A1 |
A NK1 antagonist having the formula (I), with the variables defined herein, which is useful for treating a number of disorders, including emesis, depression, anxiety and cough.
|
|
WO2002062750A9 |
There are disclosed compounds of the formula (I) a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disc...
|
|
WO/2003/063859A1 |
The present invention relates to the pharmaceutical use of selective estrogen receptor modulators (SERMs) alone or in combination with progestins for the treatment or prevention of diseases associated with elevated cartilage degradation....
|
|
WO/2003/059931A1 |
The invention relates to a process for the preparation of 7&agr −methyl hydroxy steroids of the Formula I: (Formula I)&semi wherein R1 is hydrogen, methyl or C≡CH&semi R2 is (CH2)nOH, wherein n is 0, 1 or 2&semi by a copper mediated ...
|
|
WO/2003/053991A1 |
The invention relates to a pharmaceutical composition for the treatment of psoriasis and other skin diseases. The inventive composition comprises 17-clobetasol propionate and a hydroxy derivative of progesterone having formula (I) wherei...
|
|
WO2002009683A9 |
Aldosterone blockers used for the treatment and prevention of inflammation are disclosed.
|
|
WO/2003/048181A1 |
A compound of formula (I): wherein R1 represents hydrogen, chlorine, fluorine, hydroxy or acyloxy OC(O)X, wherein X may be a linear or branched C1-6 alkyl, C3-7 cycloalky, or aryl; R2 represents C3-8 cycloalkyl or C3-8 cycloalkenyl eithe...
|
|
WO/2003/038523A2 |
Mixed carbocycle derivatives containing at least two carbocycles per molecule from the group of anthracenes, adamantanes and steroids with functionalized carbon chains are synthesized and used as modifiers of resist properties and especi...
|
|
WO/2003/029267A2 |
The invention relates to the production of 17β-(substituted)-3-oxo-&Dgr 1,2-4-azasteroids (I), wherein R1 is a C1-C4 alkyl, OR2, wherein R2 is a C1-C4 alkyl, or NR3R4, wherein R3 and R4, which may be identical or different, denote hydro...
|
|
WO/2003/011282A1 |
The present invention relates to pharmaceutical compositions, kits and methods comprising combinations of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6
,7,8-tetrahydro-naphthalene-2-ol or nontoxic pharmacologically accepta...
|
|
WO/2003/000271A2 |
The invention relates to a new method for producing radio-halogenated compounds having very high specific radioactivity. The method improves the stability of the radio-labeled compound such that its biological and/or chemical activity is...
|
|
WO/2003/000696A1 |
The present invention relates to pharmaceutical compositions and methods using such compositions for the treatment of inflammatory disease. Such compositions contain a catalyst for the dismutation of superoxide, including superoxide dism...
|
|
WO/2002/102827A1 |
The present invention is a novel process for the transformation of 11$g(b), 17$g(a) dihydroxy-6$g(a)-methylpregna-1,4-diene-3,20-dione 17-acetate (III), to 11$g(b), 17$g(a),21-trihydroxy-6$g(a)-methylpregna-1,4-diene-3,20-dio
ne 21-aceta...
|
|
WO/2002/102826A1 |
The present invention is a novel process for the transformation of 17$g(a)-hydroxy-6$g(a)-methylpregn-4-ene-3,20-dione 17-acetate (Formula (I)) to 11$g(b),17$g(a),21-trihydroxy-6$g(a)-methylpregna-1,4-diene-
3,20-dione 21-acetate (Formul...
|
|
WO/2002/094769A1 |
The invention relates to the use of poly(perfluoroalkylene)sulfonic acids for cataly-zing a reaction between carbonyl containing compounds and hydrazine or hydrazide reagents to form hydrazone derivatives. It also embraces a solid reagen...
|
|
WO/2002/078713A1 |
It is intended to provide remedies for retina and choroid diseases containing steroids as the active ingredient and having an improved effect and a dosage form for treating retina and choroid diseases whereby steroids can be conveniently...
|
|
WO/2002/076435A2 |
The invention provides use of an agent which lowers levels of 11$g(b)-HSD1 in the manufacture of a composition for the promotion of an atheroprotective lipid profile, for reducing cardiovascular disease risk, for increasing insulin sensi...
|
